What question did this study set out to answer?

This research focuses on the KCNQ2 channel as a target for developing specific epilepsy treatments. It aims to improve management strategies for neonatal epilepsies.

June 3, 2026CNS & Neurological Disorders - Drug Targets

KCNQ2 Channel as a Druggable Epilepsy Target: Advances in Pharmacological Modifiers

Q: What is the clinical evidence from this study?

Study design: Review. Population: KCNQ2-related neonatal epilepsies and Developmental and Epileptic Encephalopathy (DEE). Intervention: Pharmacological modifiers of Kv7-mediated currents (e.g., retigabine, XEN1101).

View Full Paper

Ask AI

Bookmark

Key result

Next-generation Kv7 activators offer promising therapy for KCNQ2-related encephalopathy despite limited pediatric clinical evidence.

Why the study?

Current treatments for KCNQ2-associated neonatal epilepsies are limited and not specific to Kv7.2 modulation, highlighting the need for therapies targeting underlying channel dysfunction.

Population

Patients with KCNQ2-related epilepsies, ranging from self-limited familial neonatal epilepsy to severe…

Design

Review

Authors

ILInn-Chi LeeChung Shan Medical University Hospital SYShi-Bing YangInstitute of Biomedical Sciences, Academia Sinica SWSwee‐Hee WongChung Shan Medical University Hospital

Discussion

Member takes

Implication

Supports further Kv7 activator development for KCNQ2-DEE; leaves open pediatric efficacy and safety pending dedicated trials.

Key Points

This research focuses on the KCNQ2 channel as a target for developing specific epilepsy treatments. It aims to improve management strategies for neonatal epilepsies.
Reviewed pharmacological modifiers of Kv7-mediated currents including retigabine and emerging compounds like XEN1101.
Analyzed clinical and preclinical studies on KCNQ2-targeting agents and their efficacy in seizure management.
Evaluated safety concerns, treatment responsiveness biomarkers, and neurodevelopmental impacts.
Emerging Kv7 activators like XEN1101 show improved potency and tolerability compared to traditional agents.
Clinical data indicate potential benefits in adult epilepsy, though limited evidence exists for children.
Indirect modulators may offer seizure control, but do not directly address KCNQ2 dysfunction.

Structured PICO

Population

Patients with KCNQ2-related epilepsies, ranging from self-limited familial neonatal epilepsy to severe Developmental and Epileptic Encephalopathy (DEE)

Intervention

Pharmacological modifiers of Kv7-mediated currents (e.g., retigabine, XEN1101)

Outcome

Seizure control and neurodevelopmental outcomes

Next-generation Kv7 activators show promise as mechanism-based therapies for KCNQ2-related developmental and epileptic encephalopathies, though clinical translation in neonates remains challenging.

Limitations

Safety concerns limit the clinical application of first-generation agents like retigabine
Clinical evidence for next-generation Kv7 activators in children remains limited
Challenges persist in translating in vitro efficacy into treatable clinical outcomes, particularly in neonates with DEE
Safety considerations, biomarkers of treatment responsiveness, and neurodevelopmental effects require careful evaluation
Safety concerns limit clinical application of some agents
Evidence in children remains limited

Cite This Study

Lee et al. (2026) conducted a review in KCNQ2-related neonatal epilepsies and Developmental and Epileptic Encephalopathy (DEE). Pharmacological modifiers of Kv7-mediated currents (e.g., retigabine, XEN1101) was evaluated. Next-generation Kv7 activators like XEN1101 offer promising mechanism-based therapies for KCNQ2-related developmental and epileptic encephalopathy, though clinical evidence in children remains limited.

synapsesocial.com/papers/6a1fc76ddee9eb8c0dce84c7 https://doi.org/10.2174/0118715273455571260523060433

Topics

Molecular Mechanisms of Cardiac Remodeling

View Full Paper

Ask AI

Bookmark

KCNQ2 Channel as a Druggable Epilepsy Target: Advances in Pharmacological Modifiers

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

KCNQ2 Channel as a Druggable Epilepsy Target: Advances in Pharmacological Modifiers

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider